title: Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia.
abstract: We studied the expressions of FR, FL, TR1, and TR2 on blasts and T cells from 71 patients with acute myeloid leukemia (AML) and correlated expression rates with the clinical course. Compared to AML-blasts we found higher co-expressions on healthy myeloid and T cells. Expression of all markers on blasts and on T cells was similar in different subtypes and acute stages of AML. Compared to the non-responders (n = 7) responders to the AML Cooperative Group-therapy (n = 22) presented with higher proportions of blasts co-expressing the four markers (FR: 32 vs 15%; FL: 15 vs 13%; TR1: 72 vs 37%; TR2: 24 vs 23%) or T cells (FR: 88 vs 71%; FL: 76 vs 56%; TR1: 96 vs 44%; TR2: 54 vs 42%). Patients with higher expression rates of TR1 on blasts (≥ 48%) and on T cells (≥ 67%) were characterized by a prolonged survival. In summary, our data show a variable expression of FR, FL, TR1 and TR2 on blasts or T cells in different subgroups of AML. Higher co-expression rates of FR, FL, TR1 and TR2 were characterized by a better prognosis for the patients with respect to achieve a remission and to survive. Functional analyses should be performed to find out those patients in who induced upregulation of these markers could contribute to overcome drug resistance.
authors.affiliation: Medical Department III, Klinikum Grosshadern, University of Munich, Germany.
authors.forename: Sandra
authors.initials: S
authors.lastname: Pordzik
authors.forename: Karin
authors.initials: K
authors.lastname: Petrovici
authors.forename: Christoph
authors.initials: C
authors.lastname: Schmid
authors.forename: Tanja
authors.initials: T
authors.lastname: Kroell
authors.forename: Cornelia
authors.initials: C
authors.lastname: Schweiger
authors.forename: Claus-Henning
authors.initials: CH
authors.lastname: Köhne
authors.forename: Helga
authors.initials: H
authors.lastname: Schmetzer
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D053222:Fas Ligand Protein / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D055815:Young Adult; D019014:fas Receptor / Q000378:metabolism*
chemical_list: D053222:Fas Ligand Protein; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D019014:fas Receptor